Heck M M, Höppner M, Horn T, Thalgott M, Gschwend J E, Retz M
Urologische Klinik und Poliklinik, Klinikum rechts der Isar, Technische Universität München, Ismaninger Straße 22, 81675 München, Deutschland.
Urologe A. 2012 Mar;51(3):390-7. doi: 10.1007/s00120-012-2804-y.
First clinical experiences with abiraterone and cabazitaxel for the treatment of metastatic castration-resistant prostate cancer patients following docetaxel chemotherapy are reported.
We describe PSA response rates and disease control rates determined by imaging studies at 3 months as well as side effects in the daily routine. All patients were treated within the"compassionate use" programs of cabazitaxel and abiraterone or treated according to their inclusion and exclusion criteria at the "Technische Universität München".
Of 54 patients, 15 were treated with cabazitaxel and 39 with abiraterone. In patients treated with cabazitaxel, after 3 months of therapy the PSA reduction rate > 50% was 46.2%, the PSA progression rate was 15.4%, and the disease control rate was 83.3%. Main grade 3/4 hematotoxicities were neutropenia (40%) and anemia (20%). Febrile neutropenia was observed in 2 of 15 (13.3%) patients. Main non-hematological grade 3/4 toxicities were diarrhea (13.3%) and polyneuropathy (13.3%). In patients treated with abiraterone, after 3 months of therapy the PSA reduction rate >50% was 35.1%, the PSA progression rate was 46.0%, and the disease control rate was 47.1%. Main grade 3/4 hematotoxicities were anemia (5.1%) and thrombocytopenia (5.1%). Main non-hematological toxicities were fatigue (20.5%), sweating (17.9%), and constipation (10.3%).
Utilization of cabazitaxel and abiraterone in the daily routine show response rates comparable to their approval studies with acceptable side effects.
报告阿比特龙和卡巴他赛用于多西他赛化疗后转移性去势抵抗性前列腺癌患者治疗的首批临床经验。
我们描述了3个月时通过影像学研究确定的PSA缓解率和疾病控制率以及日常的副作用。所有患者均在卡巴他赛和阿比特龙的“同情用药”项目中接受治疗，或根据“慕尼黑工业大学”的纳入和排除标准进行治疗。
54例患者中，15例接受卡巴他赛治疗，39例接受阿比特龙治疗。接受卡巴他赛治疗的患者，治疗3个月后，PSA降低率>50%为46.2%，PSA进展率为15.4%，疾病控制率为83.3%。主要的3/4级血液学毒性为中性粒细胞减少（40%）和贫血（20%）。15例患者中有2例（13.3%）出现发热性中性粒细胞减少。主要的非血液学3/4级毒性为腹泻（13.3%）和多发性神经病变（13.3%）。接受阿比特龙治疗的患者，治疗3个月后，PSA降低率>50%为35.1%，PSA进展率为46.0%，疾病控制率为47.1%。主要的3/4级血液学毒性为贫血（5.1%）和血小板减少（5.1%）。主要的非血液学毒性为疲劳（20.5%）、出汗（17.9%）和便秘（10.3%）。
在日常临床中使用卡巴他赛和阿比特龙显示出与获批研究相当的缓解率，且副作用可接受。
